Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from asn-linked oligosaccharides

Journal of Biochemistry

Volumn 140, Issue 6, 2006, Pages 777-783

  Shoji Hosaka, Emi ^a   Kobayashi, Yukari ^a   Wakitani, Masako ^a   Uchida, Kazuhisa ^a   Niwa, Rinpei ^a   Nakamura, Kazuyasu ^a   Shitara, Kenya ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Cytotoxicity; Defucosylation; Fc fusion; Fc RIIIa; Oligosaccharide

Indexed keywords

ALPHA 1,6 FUCOSYLTRANSFERASE; ASPARAGINE; FC RECEPTOR; FC RECEPTOR IIIA; FUCOSE; FUCOSYLTRANSFERASE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MONOSACCHARIDE; OLIGOSACCHARIDE; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; ALEFACEPT; FCGR3A PROTEIN, HUMAN; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CONTROLLED STUDY; CYTOTOXICITY; FUCOSYLATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CHEMISTRY; CHO CELL; CRICETULUS; DRUG EFFECT; HAMSTER; IMMUNOLOGY;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD58; CHO CELLS; CRICETINAE; CRICETULUS; FUCOSE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; OLIGOSACCHARIDES; RECEPTORS, IGG; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS;

EID: 34250682223     PISSN: 0021924X     EISSN: None     Source Type: Journal    
DOI: 10.1093/jb/mvj207     Document Type: Article

References (49)

1. Carter, P. (2001) Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1, 118-129
2. Glennie, M.J. and van de Winkel J.G.J. (2003) Renaissance of cancer therapeutic antibodies. Drug Discovery Today 8, 503-510
3. Smith, M.R. (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22, 7359-7368
4. Clynes, R.A., Towers, T.L., Presta, L.G., and Ravetch, J.V. (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6, 443-446
5. Cartron, G., Dacheux, L., Salles, G, Solal-Celigny, P., Bardos, P., Colombat, P., and Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99, 754-758
6. Anolik, J.H., Campbell, D., Felgar, R.E., Young,F., Sanz,I., Rosenblatt,J., and Looney, R.J. (2003) The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48, 455-459
7. Weng, W.K. and Levy, R. (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21, 3940-3947
8. Koene, H.R., Kleijer, M., Algra, J., von Roos, D., dem Born, A.E., and de Haas, M. (1997) FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48L/R/H phenotype. Blood 90, 1109-1114
9. Wu, J., Edberg, J.C., Redecha, P.B., Bansal, V., Guyre, P.M., Coleman, K., Salmon, J.E., and Kimber;y, R.P. (1997) A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. 100, 1059-1070
10. Leget, G.A. and Czuczman, M.S. (1998) Use of rituximab, the new FDA-approved antibody. Curr. Opin. Oncol. 10, 548-551
11. Gopal, A.K. and Press, O.W. (1999) Clinical applications of anti-CD20 antibodies. J. Lab .Clin. Med. 134, 445-450
12. Kumpel, B.M., Rademacher, T.W., Rook, G.A., Williams, P.J., and Wilson, I.B. (1994) Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. Hum. Antib. Hybrid 5, 143-151
13. Kumpel, B.M., Wang, Y., Griffiths, H.L., Hadley, A.G., and Rook, G.A. (1995) The biological activity of human monoclonal IgG anti-D is reduced by beta-galactosidase treatment. Hum. Antib. Hybrid 6, 82-88
14. Umana, P., Jean-Mairet, J., Moudry, R., Amstutz, H., and Bailey, J.E. (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17, 176-180
15. Davies, J., Jiang, L., Pan, L.Z., LaBarre, M.J., Anderson, D,. and Reff, M. (2001) Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcγRIII. Biotechnol. Bioeng. 74, 288-294
16. Shields, R.L., Lai, J., Keck, R. O'Connell, L.Y., Hong, K., Meng,Y.G., Weikert, S.H.A., and Presta, L.G. (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277, 26733-26740
17. Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., Hanai,N. and Shitara, K. (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278, 3466-3473
18. Niwa, R., Shoji-Hosaka, E., Sakurada, M., Shinkawa, T., Uchida, K., Nakamura, K., Matsushima, K., Ueda, R., Hanai,N. and Shitara, K. (2004) Defucosylated anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T cell leukemia and lymphoma. Cancer Res. 64, 2127-2133
19. Yamane-Ohnuki, N., Kinoshita, S., Inoue-Urakubo, M., Kusunoki, M., Iida,S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., Shitara, K., and Satoh, M. (2004) Establishment of FUT8 knock-out CHO cells; an ideal host cell line for producing completely defucosylated antibodies with enhanced ADCC. Biotechnol. Bioeng. 87, 14-22
20. Chamow, S.M. and Ashkenari, A. (1996) Immunoadhesions: principles and applications. Trends in Biotechnol. 14, 52-60
21. Mohler, K.M., Torrance, D.S., Smith, C.A., Goodwin, R.G., Stremler, K.E., Fung, V.P., Madani, H., and Widmer, M.B. (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151, 1548-1561
22. Moreland, L.W., Baumgaetner, S.W., Schiff, M.H., Tindall, E.A., Fleischmann, R.M., Weaver, A.L., Ettlinger, R.E., Cohen, S., Koopman, W.J., Mohler, K., Widmer, M.B., and Blosch,C.M. (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141-147
23. Moreland, L.W., Schiff, M.H., Baumgartner, S.W., Tindall, E.A., Fleischmann, R.M., Bulpitt, K.J., Weaver, A.L., Keystone, E.C., Furst, D.E., Mease, P.J., Ruderman, E.M., Horwitz, D.A., Arkfeld, D.G., Garrison, L., Burge, D.J., Blosch, C.M., Lange, M.L.M., McDonnell, N.D., and Weinblatt, M.E. (1999) Etanercept therapy in rheumatoid arthritis. Ann. Intern. Med. 130, 478-486
24. Mathias, S.D., Colwell, H.H., Miller,D.P., Moreland, L.W. Buatti, M., and Wanke, L. (2000) Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin. Ther. 22, 128-139
25. Korth-Bradley, J.K., Rubin, A.S., Hanna, R.K., Simcoe, D.K., and Lebsack, M.E. (2000) The pharmacokinetics of etanercept in healthy volunteers. Ann. Pharmacother. 34, 161-164
26. Miller, G.T., Hochman, P.S., Meier, W., Tizard, R., Bixler, S.A., Rosa, M.D., and Wallner, B.P. (1993) Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J. Exp. Med. 178, 211-222
27. Majeau, G.R., Meier, W., Jimmo, B., Kioussis, D., and Hochman,P.S. (1994) Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. J. Immunol. 152, 2753-2766
28. Kruger,G.G. (2004) Current concepts and review of alefacept in the treatment of psoriasis. Dermatol. Clin. 22, 407-426
29. Bashir, S.J. and Maibach, H.I. (2001) Alefacept. Curr. Opin. Investig. Drugs 2, 631-634
30. + human T cells. Eur. J. Immunol. 33, 666-675
31. da Silva, A.J., Brickelmaier, M., Majeau, G.R., Li, Z., Su, L., Hsu, Y.M. and Hochman, P.S. (2002) Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J. Immunol. 168, 4462-4471
32. Niwa,R., Natsume,A., Uehara,A., Wakitani,M., Iida,S., Uchida,K., Satoh,M. and Shitara,K. (2005) Effect of fucose removal on effector functions of different IgG subclasses. J. Immunol. Methods 306, 151-160
33. Natsume,A., Wakitani,M., Yamane-Ohnuki,N., Shoji-Hosaka,E., Niwa,R., Uchida,K., Satoh,M. and Shitara,K. (2005) Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded Fc fusion protein comprising an single-chain antibody linked the antibody constant region. J. Immunol. Methods 306, 93-103
34. Perez, C., Albert, I., DeFay, K., Zachariades, N., Gooding, L., and Kriegler, M. (1990) A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63, 251-258
35. Nakamura, K., Tanaka, Y., Fujino, I., Hirayama, N., Shitara, K. and Hanai, N. (2000) Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody. Mol. Immunol. 37, 1035-1046
36. Flick, D.A. and Gifford, G.E. (1984) Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J. Immunol. Methods 68, 167-175
37. Seckinger, P., Isaaz, S., and Dayer, J. (1989) Purification and biologic characterization of a specific tumor necrosis factor a inhibitor. J. Biol. Chem. 264, 11966-11973
38. Okazaki, A., Shoji-Hosaka, E., Nakamura, K., Wakitani, M., Uchida, K., Kakita, S., Tsumoto, K., Kumagai, I. and Shitara, K. (2004) Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgRIIIa. J. Mol. Biol. 336, 1239-1249
39. Niwa, R., Shoji-Hosaka, E., Sakurada, M., Kobayashi, Y., Uehara, A., Yokoi, H., Nakamura, K., and Shitara, K. (2004) Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcγRIIIa functional polymorphism. Clin.Cancer Res. 10, 6248-6255
40. Pennica, D., Lam, V.T., Weder, R.F., Kohr, W.J., Basa, L.J., Spellman, M.W., Ashkenazi, A., Shire, S.J., and Goeddel, D.V. (1993) Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor. Biochemistry 32, 3131-3138
41. Meier, W., Gill, A., Rogge, M., Dabora, R., Majeau, G.R., Oleson, F.B., Jones, W.E., Frazier, D., Miatkowski, K., and Hochman, P.S. (1995) Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Ther. Immunol. 2, 159-171
42. Schall, T.J., Lewis, M., Koller, K.J., Lee, A., Rice, G.C., Wong, G.H., Gatanaga, T.,. Granger, G.A, Lentz, R., and Raab, H. (1990) Molecular cloning and expression of a receptor for human necrosis factor. Cell 61, 361-370
43. Smith, C.A., Davis, T., Anderson, D., Solam, L., Beckmann, M.P., Jerzy, R., Dower, S.K., Cosman, D. and Goodwin, R.G. (1990) A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248, 1019-1023
44. Ortonne, J., Lebwohl, M., and Griffiths, C.E. (2003) Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur. J. Dermatol. 13, 117-123
45. Gordon, K.B., Vaishnaw, A.K., O'Gorman, J., Haney, J., and Menter, A. (2003) Treatment of psoriasis with alefacept. Arch. Dermatol. 139, 1563-1571
46. Van den Brande, J.H., Braat, H., Van den Bronk, G., Versteeg, H., Bauer, C.A., Hoedemaeker, I., Van Monterans, C., Hommes, D.W., Peppelenbosch, M.P., and Van Deventer, S.H. (2003) Infliximab but not Etanercept induces apoptosis in lamina propia T-lymphocytes from patients with crohn's disease. Gastroenterology 124, 1774-1785
47. Lugering, A., Schmidt, M., Lugering, N., Pauels, H., Domschke, W., and Kucharzik, T. (2001) Infliximab induces apoptosis in mococytes from patients with chronic active crohn's disease by using a caspase-dependent pathway. Gastroenterology 121, 1145-1157
48. Sandborn, W.J., Hanauer, S.B., Katz, S., Safdi, M., Wolf, D.G., Baerg, R.D., Tremaine, W.J., Johnson, T., Diehl, N.N. and Zinsmeister, A.R. (2001) Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterlogy 121, 1088-1094
49. Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X., Shealy, D., and Wagner, C. (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Thera. 301, 418-426